Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/28/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Janusz Rak?

Janusz Rak

Assifesnt Professor

Henderson Research Centre

HQ Phone:  (905) 527-2299

Direct Phone: (905) ***-**** ext. *****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Henderson Research Centre

40 Wing, Ground Floor 711 Concession Street

Hamilton, Ontario,L8V 1C3

Canada

Company Description

The Henderson Research Centre (HRC) was established in 1988 as a joint initiative of the Hamilton Health Sciences and McMaster University. The Henderson Research Centre has three main programmes which interact closely. These are: Experimental Thrombosis and ...more

Web References(93 Total References)


Henderson Research Centre - Thrombosis and Vascular Disease - Hamilton

www.hendersonresearchcentre.com [cached]

Dr. Janusz Rak


Henderson Research Centre - Thrombosis and Vascular Disease - Hamilton

www.hendersonresearchcentre.com [cached]

Dr. Janusz Rak (faculty)


Henderson Research Centre - Thrombosis and Vascular Disease - Hamilton

www.hendersonresearchcentre.com [cached]

Dr. Janusz RakHenderson Research Centre - Thrombosis and Vascular Disease - HamiltonDr Janusz Rak graduated medicine and received his medical licence at the Medical Academy in Wroclaw, Poland.He received his PhD degree in tumor biology from the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences in 1986 for studies on transplantable tumor models as predictors of treatment efficacy in cancer, changes in tumor-host interactions resulting from anti-cancer treatment, and interactions between tumor cells and the vasculature in the course of cancer metastasis. In 1988, as a recipient of the Fullbright-Hays Postdoctoral Scholarship he joined the Michigan Cancer Foundation (MCF) in Detroit, Michigan, where he worked with Drs Fred and Bonnie Miller, and Gloria Heppner on tumor cell heterogeneity, tumor cell interactions in metastasis, alterations in cancer cell glycosylation and the role of ras oncogene in tumor progression.Some of these themes accompanied Dr Rak during his subsequent postdoctoral work with Dr Robert S. Kerbel at the University of Torono.Dr Rak joined the Henderson Research Centre in 2000 as an Assistant Professor affiliated with the Department of Medicine and the Division of Oncology, McMaster University.His laboratory is currently pursuing studies on the relationship between angiogenesis and various activities of the hemostatic system both, in cancer and in other 'angiogenesis -dependent' diseases. Dr Rak is an author or co-author of over 70 publications, recipient of peer-reviewed grants from the National Cancer Institute of Canada (NCIC) and Natural Sciences and Engineering Research Council of Canada (NSERC), and a reviewer for several research journals (Lancet, Journal of Cell Science, Cancer Research, International Journal of Cancer and others).


Endowed Chair | The Cole Foundation

colefoundation.ca [cached]

Janusz Rak
Janusz Rak, MD, PhD has held the Jack Cole Chair in Pediatric Oncology and Hematology since April of 2006, when he joined McGill as an Associate Professor in the Department of Pediatrics and an Associate Member of the Division of Experimental Medicine (Department of Medicine). He is also a researcher in the Cancer Axis at the Research Institute of the McGill University Health Centre at the Montreal Children's Hospital. Dr. Rak graduated from the Medical Academy in Wroclaw, Poland, in 1980. He received his PhD in tumor biology from the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, in 1986 for studies on transplantable tumor models as predictors of treatment efficacy in cancer, changes in tumor-host interactions resulting from anti-cancer treatment, and interactions between tumor cells and the vasculature in the course of cancer metastasis. In 1988, as a recipient of the Fulbright-Hays Postdoctoral Scholarship, he joined the Michigan Cancer Foundation in Detroit, Michigan, where he worked on tumor cell heterogeneity, tumor cell interactions in metastasis, alterations in cancer cell glycosylation, and the role of ras oncogene in tumor progression. Dr. Rak pursued similar areas of research during his subsequent postdoctoral work with Dr. Robert S. Kerbel at the University of Toronto. In 2000, Dr. Rak joined the Henderson Research Centre at McMaster University, where he held the title of Assistant Professor affiliated with the Department of Medicine and the Division of Oncology until coming to McGill. Dr. Rak's research revolves around understanding the role of the vascular system in the development, progression, and responsiveness to therapy of human cancers, particularly those affecting children. In fact, it is now known that pediatric malignancies, including leukemia, are dependent on processes of vascular growth (angiogenesis), as blood vessels 'communicate' with and stimulate cancer cells in a number of ways. Dr. Rak pioneered studies on the interrelationship between genetic tumor progression (i.e. the action of oncogenes, tumor suppressor genes, and aberrant intracellular signaling pathways) in the regulation of angiogenic and procoagulant properties of cancer cells and their related capacity to use the vascular system as a vehicle for tumor growth and spreading. His laboratory is studying the role of molecules such as tissue factor (TF), vascular endothelial growth factor (VEGF), and thrombospondin (TSP-i) in these processes. Trie lab also studies interactions between cancer cells, their associated stroma, blood vessels, and blood in generating conditions for aggressive tumor growth. In so doing, they concurrently explore the role of drugs targeting oncogenes (targeted agents), blood vessels (antiangiogenic agents), and the coagulation system (anticoagulants) in bringing such growth under control. Dr. Rak is also probing why traditional and novel treatments (e.g. antiangiogenesis) are sometimes ineffective in treating cancers (e.g. due to drug resistance), and he aims to find ways to use these agents more effectively. By better understanding how tumors interact with blood vessels, and how these interactions differ between malignancies affecting adults and children, Dr. Rak's research will hopefully lead to better treatment of cancers affecting children.


Chaire dotée - La Fondation Cole | The Cole Foundation

colefoundation.ca [cached]

Janusz Rak
Janusz Rak, MD, PhD has held the Jack Cole Chair in Pediatric Oncology and Hematology since April of 2006, when he joined McGill as an Associate Professor in the Department of Pediatrics and an Associate Member of the Division of Experimental Medicine (Department of Medicine). He is also a researcher in the Cancer Axis at the Research Institute of the McGill University Health Centre at the Montreal Children's Hospital. Dr. Rak graduated from the Medical Academy in Wroclaw, Poland, in 1980. He received his PhD in tumor biology from the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, in 1986 for studies on transplantable tumor models as predictors of treatment efficacy in cancer, changes in tumor-host interactions resulting from anti-cancer treatment, and interactions between tumor cells and the vasculature in the course of cancer metastasis. In 1988, as a recipient of the Fulbright-Hays Postdoctoral Scholarship, he joined the Michigan Cancer Foundation in Detroit, Michigan, where he worked on tumor cell heterogeneity, tumor cell interactions in metastasis, alterations in cancer cell glycosylation, and the role of ras oncogene in tumor progression. Dr. Rak pursued similar areas of research during his subsequent postdoctoral work with Dr. Robert S. Kerbel at the University of Toronto. In 2000, Dr. Rak joined the Henderson Research Centre at McMaster University, where he held the title of Assistant Professor affiliated with the Department of Medicine and the Division of Oncology until coming to McGill. Dr. Rak's research revolves around understanding the role of the vascular system in the development, progression, and responsiveness to therapy of human cancers, particularly those affecting children. In fact, it is now known that pediatric malignancies, including leukemia, are dependent on processes of vascular growth (angiogenesis), as blood vessels 'communicate' with and stimulate cancer cells in a number of ways. Dr. Rak pioneered studies on the interrelationship between genetic tumor progression (i.e. the action of oncogenes, tumor suppressor genes, and aberrant intracellular signaling pathways) in the regulation of angiogenic and procoagulant properties of cancer cells and their related capacity to use the vascular system as a vehicle for tumor growth and spreading. His laboratory is studying the role of molecules such as tissue factor (TF), vascular endothelial growth factor (VEGF), and thrombospondin (TSP-i) in these processes. Trie lab also studies interactions between cancer cells, their associated stroma, blood vessels, and blood in generating conditions for aggressive tumor growth. In so doing, they concurrently explore the role of drugs targeting oncogenes (targeted agents), blood vessels (antiangiogenic agents), and the coagulation system (anticoagulants) in bringing such growth under control. Dr. Rak is also probing why traditional and novel treatments (e.g. antiangiogenesis) are sometimes ineffective in treating cancers (e.g. due to drug resistance), and he aims to find ways to use these agents more effectively. By better understanding how tumors interact with blood vessels, and how these interactions differ between malignancies affecting adults and children, Dr. Rak's research will hopefully lead to better treatment of cancers affecting children.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory